Company News

First patient treated with new extended dosing of OVM-200 cancer vaccine

Company News /

Extended dosing of OVM-200, Oxford Vacmedix’s lead cancer vaccine, has been approved by the MHRA for use in the ongoing Phase 1 clinical trial Oxford, UK – 20th February 2025 Press Release: First patient treated with new exetended dosing of OVM-200 Oxford Vacmedix (OVM) announced today the first patient being treated with new extended dosing […]

First patient treated with new extended dosing of OVM-200 cancer vaccine Read More »

Oxford Vacmedix announces major milestone for lead cancer vaccine OVM-200

Company News /

OVM-200 Drug Product, manufactured to Good Manufacturing Process (GMP), has been certified stable and sterile four years post manufacture – a major milestone for OVM-200 development.   Oxford, UK – 23rd January 2025 Press Release – OVM-200 Drug Product 4 year stability Oxford Vacmedix (OVM), the UK-based biopharma company developing therapeutic cancer vaccines, announced today

Oxford Vacmedix announces major milestone for lead cancer vaccine OVM-200 Read More »

Oxford Vacmedix appoints Dr Nam Park as Chief Business Officer

Company News, Investor News /

The appointment of Dr Nam Park as Chief Business Officer brings further expertise in venture financing and capital markets to Oxford Vacmedix Oxford, UK – 16th January 2025 Press Release – Appointment of Dr Nam Park 16-Jan-25 Oxford Vacmedix (OVM), the UK-based biopharma company focused on development of therapeutic cancer vaccines, announced today that Dr

Oxford Vacmedix appoints Dr Nam Park as Chief Business Officer Read More »

Innovate UK award to OVM for clinical development of OVM-200

Company News, Investor News /

Oxford Vacmedix receives an Investor Partnership award from Innovate UK for the clinical development of lead cancer vaccine OVM-200. Oxford, UK _ 9 January 2025 Press Release – Innovate UK Award 09-Jan-25 Oxford Vacmedix (OVM), the UK-based biopharma company developing vaccines to treat cancer, confirmed today the grant of a prestigious Investor Partnership award from

Innovate UK award to OVM for clinical development of OVM-200 Read More »

Oxford Vacmedix licenses OVM-200 to Dx&Vx

Company News /

Oxford Vacmedix licences cancer vaccine OVM-200 to leading shareholder Dx&Vx, for development in South Korea, China, and India. Oxford, UK – 13th December 2024 Press release – OVM-200 licenced to Dx&Vx Oxford Vacmedix (OVM), the UK-based biopharma company developing vaccines to treat cancer, announced today the finalisation of a licensing deal for its lead cancer

Oxford Vacmedix licenses OVM-200 to Dx&Vx Read More »

UK charity Prostate Cancer Research invests in Oxford Vacmedix Series B

Company News, Investor News /

Support from leading Prostate cancer charity for the clinical development of OVM-200. Oxford, UK – 27th November 2024 Press Release – Prostate Cancer Research invests in Oxford Vacmedix Series B Oxford Vacmedix (OVM), the UK-based biopharma company developing vaccines to treat cancer, announced today Series B investment from Proven Connect, the translational arm of the charity

UK charity Prostate Cancer Research invests in Oxford Vacmedix Series B Read More »

Oxford Vacmedix announces lead investment for Series B fund

Company News, Investor News /

Lead investment of $3.0 million in Oxford Vacmedix Series B from existing investors. Oxford, UK – 6th November 2024 Press Release – Oxford Vacmedix announces lead investment for Series B fund Oxford Vacmedix (OVM), the UK-based biopharma company developing vaccines to treat cancer announced today the lead investment in its Series B fund of $3.0m

Oxford Vacmedix announces lead investment for Series B fund Read More »

Oxford Vacmedix announces grant from Innovate UK for OVM-200 clinical trial

Company News /

Prostate Cancer Research’s Proven Connect supports grant application and facilitates additional funding for the clinical development of OVM’s lead cancer vaccine, OVM-200. Oxford – 31st July 2024 Press Release – Oxford Vacmedix announces grant from Innovate UK for OVM-200 clinical trial Oxford Vacmedix (OVM), developing therapeutic cancer vaccines, announced today the grant of a prestigious

Oxford Vacmedix announces grant from Innovate UK for OVM-200 clinical trial Read More »

Oxford Vacmedix wins 1st prize in 2024 Talent, Innovation and Entrepreurship Competition

Company News /

Oxford Vacmedix has won the 1st prize in the China Overseas Talents Competition (UK Division)   The UK section of the competition was held in London on 14th June 2024 and Oxford Vacmedix won 1st prize from a strong field of 25 competitors. The international judges were impressed by the company’s groundbreaking ROP (Recombinant Overlapping

Oxford Vacmedix wins 1st prize in 2024 Talent, Innovation and Entrepreurship Competition Read More »

Regulatory approval of novel TB diagnostic in China granted to OVM licensee CBI

Company News /

Regulatory approval of novel TB diagnostic in China granted to Oxford Vacmedix licensee Changzhou Biotech First regulatory approval worldwide for any application of the Recombinant Overlapping Peptide (ROP) technology Oxford, UK – 25th April 2024 Press Release – Regulatory approval granted for novel TB diagnostic Oxford Vacmedix (OVM), the UK-based biopharma company developing vaccines to

Regulatory approval of novel TB diagnostic in China granted to OVM licensee CBI Read More »